Odyssey Therapeutics Raises $279M in Upsized US IPO

IPO Success and Market Debut

Biopharmaceutical company Odyssey Therapeutics announced it has successfully raised $279 million in an upsized U.S. initial public offering. The company sold 15.5 million shares priced at $18 each, which was at the top end of its marketed range. The company will begin trading on the Nasdaq exchange under the ticker symbol ODTX.

Biotech IPO Market Revival

Odyssey's successful offering comes amid a recent revival in the U.S. biotech IPO market. Several other drug developers have recently tapped equity markets, including Seaport Therapeutics, Hemab Therapeutics, and Alamar Biosciences. This trend indicates growing investor confidence in the biotechnology sector.

Company Focus and Use of Proceeds

Founded in 2021, Odyssey Therapeutics focuses on developing treatments for autoimmune and inflammatory diseases. Its lead candidate, OD-001, is currently in a mid-stage trial for ulcerative colitis. The company plans to use the proceeds from the offering primarily to fund the clinical development of OD-001 and for other general corporate purposes. J.P. Morgan, TD Cowen, and Cantor served as underwriters for the offering.

Outlook

The successful IPO provides Odyssey Therapeutics with significant capital to advance its clinical pipeline. The market will be closely watching the progress of its lead drug candidate and the performance of its stock as it begins trading, which may serve as a further barometer for the health of the biotech IPO landscape.

FAQ

Q: How much did Odyssey Therapeutics raise in its IPO?
A: Odyssey Therapeutics raised $279 million by selling 15.5 million shares at $18 per share.

Q: What is Odyssey Therapeutics' stock symbol?
A: The company will trade on the Nasdaq under the symbol ODTX.

Q: What is the company's primary focus?
A: The company develops treatments for autoimmune and inflammatory diseases, with its lead candidate targeting ulcerative colitis.

Source: Investing.com